Catalent, a global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, announced that it has received a project grant as part of a consortium.
Catalent, a global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, announced that it has received a project grant as part of a consortium looking to evaluate, develop and manufacture thermo stable and cold-chain independent nano-pharmaceutical virosome-based vaccine candidates. Currently, 90% of existing vaccines are cold-chain dependent, and the goal of the consortium is to develop a scalable manufacturing process for vaccines that are stable and temperature independent.
